Background: Increasing evidence suggests that perioperative factors including anaesthetics influence cancer recurrence and metastasis after surgery. This study investigated the influence of sevoflurane on the response of lung and renal cancer cells to cisplatin, with focus on transforming growth factor-beta (TGF-b) and osteopontin (OPN) that are both closely associated with cancer tumorigenesis and metastasis. Methods: Non-small cell lung adenocarcinoma (A549) and renal cell carcinoma (RCC4) cells were exposed to 3.6% sevoflurane for two hrs. Malignant potential represented by cell viability, migration, chemosensitivity to cisplatin was evaluated. Expression of OPN, TGF-b1, TGF-b receptor type II (TGF-bRII) and the canonical downstream effector Smad3 was assessed. SiRNA knockdown of TGF-b1 and OPN and chemical inhibition of TGF-bRI/II was performed. Results: Sevoflurane reduced cell viability (0.394) versus control (0.459) (P < 0.01), enhanced chemosensitivity but had no effect on migration of A549 cells. It enhanced viability (0.467) versus control (0.347) (P < 0.001), chemoresistance and migration of RCC4. In A549, there was enhanced nuclear Smad3. In RCC4, TGF-bRII and OPN were upregulated, while TGF-b1 was over-expressed with reduced nuclear Smad3. TGF-bRII inhibition and OPN knockdown abolished sevoflurane-mediated viability, and migration, respectively, in RCC4. Conclusions: Sevoflurane promotes the metastatic potential of renal carcinoma, but not of non-small cell lung cancer. This may be associated with its differential effect on cellular signalling including TGF-b. Our findings indicate that sevoflurane may have different effects on the metastatic potential and chemosensitivity of different tumour types.
Surgical excision is the primary treatment for most solid malignancies. Despite extensive surgical resection, the existence of minimal residual disease can lead to a high incidence of cancer recurrence and metastasis postoperatively, and is the leading cause of death in cancer patients. 1 Survival and progression of these residual cancer cells depends on multiple synergistic perioperative factors, which may include anaesthetics and analgesics. 2 Volatile anaesthetics are used extensively in surgical oncology. In vitro study has indicated a differential effect on tumours, with sevoflurane inhibiting ADC 3 and colon cancer; 4 but potentiating breast 5 and ovarian cancer. 6 However, the molecular mechanisms underlying these effects are unknown. Investigation of direct effects of volatile agents on malignant molecular processes has thus far largely focused on receptor tyrosine kinase-dependent pathways. However, transforming growth factor-b (TGF-b) signaling could be implicated. 7 This signal transduction network is involved in regulation of a number of developmental processes including growth and cellular differentiation, proliferation, migration, adhesion and apoptosis. TGF-b binding to the cell surface TGF-b type I/II receptor complex initiates a phosphorylation cascade of intracytoplasmic effectors. The TGF-b family share a canonical signaling pathway, 'similar to Mothers against Decapentaplegic' (Smad). Receptor-regulated Smad proteins (Smad2/3) combine with common-mediator Smad4 to regulate transcription of target genes. Non-canonical or 'non-Smad' signaling also occurs, alongside cross-talk with other pathways, resulting in wide ranging effects of TGF-b signaling. 8 Osteopontin (OPN) is a secreted phosphoprotein normally expressed in bone and epithelial cells including the lung bronchi and renal tubules. Overexpression is observed in many cancers, 9 and it is associated with invasion and metastasis, including in lung cancer. 10 Cisplatin is a cytotoxic chemotherapeutic agent routinely used in the treatment of solid malignancies, including renal cell carcinoma (RCC) and non-small-cell lung adenocarcinoma (ADC). These aggressive carcinomas commonly develop chemoresistance clinically and were therefore selected for this study.
The aim of this study was to investigate the effect of sevoflurane on cell viability, migration and chemoresistance to cisplatin of ADC and RCC cell lines, and the role of TGF-b and OPN signaling in the mechanism of sevoflurane-mediated effects.
Methods

Cell culture
Human non-small cell lung adenocarcinoma A549 and renal cell carcinoma RCC4 cell lines were cultured in 75 cm 2 penicillin-streptomycin (Invitrogen). Cells were maintained at 37 C in humidified air with 5% CO 2 .
Sevoflurane exposure
Before gas exposure, cells were split and seeded at equal cell density in 30-mm2 Petri dishes (VWR, Leicestershire, UK) and 6, 24 and 96-well plates, and incubated at 37 C and 5% CO 2 . When cultures reached 70-80% confluence, cell media was replenished and plates were placed in a 1.5 L purpose-built airtight, temperature-controlled gas chamber with inlet and outlet valves and an internal electric fan to ensure mixture of gases. For sevoflurane delivery, the chamber inlet was connected to a closed gas delivery system consisting of a calibrated oxygen flow meter and an inline sevoflurane vaporizer (Abbott Laboratories, Maidenhead, UK). Outlet gas was analysed (Datex gas monitor, Helsinki, Finland) until a sevoflurane concentration of 3.6% (equivalent MAC value to 2% isoflurane) 6 11 was reached from 2L/min flow air carrier gas (oxygen 21%) balanced with 5% carbon dioxide (CO2), with gas flow delivery continuing for a minimum of 5 min to ensure equilibration. Cells were incubated in the sealed chamber for two h at 37 C before they were returned to the standard cell culture incubator at maintenance conditions. Cells in the control group were placed in an identical chamber with 21% oxygen and 5% CO 2 . Cells in the naïve group remained in the standard cell culture incubator throughout. An exposure duration of two h was used, in accordance with previous studies, 6 11 as this is a reasonable minimum duration for abdominal and thoracic cancer surgery.
Treatment with chemotherapeutic agent
Cisplatin [cis-diammine (cyclobutane-1,1-dicarboxylato) platinum(II)] (DDP) is a well-established cytotoxic agent for solid malignancies. 1mM stock solution (Calbiochem, USA, Cat 232120) was diluted with RPMI media to make a clinically relevant concentration of 80 mM DDP-supplemented media.
Just before gas exposure, cells were treated with or without DDP-supplemented media and 24 h later reverted back to standard RPMI media.
Cell viability assay
Cells were split into 96-well plates and incubated overnight. Cells were treated with or without 80 mM DDP-supplemented media, and exposed to sevoflurane gas for two h. At 18 h post gas exposure, 10% Alamar Blue™ was added to each well and incubated in the dark at 37
C for six h. Absorbance was measured at 540 nm. Recordings were blanked using media and media-DDP only wells and negative controls provided by wells with media/ media-DDP plus Alamar Blue™ but no cells. For TGF-bRI/II inhibition, cells were incubated in media containing 5-20 mM LY2109761 (LY21) (Santa Cruz Biotechnology, Inc Cat SC-396262), a dual inhibitor of TGF-b receptor I/II kinases (IC 50 ¼69 nM), concentration optimised to cell line, for two h pregas exposure.
Wound healing (migration) assay
Cell migration was assessed using a method as previously described. 12 After cultured cells reached full confluence in six or 24-well plates, an artificial gap was created by scratching with a sterile plastic pipette tip (1000 mL) to form a 'cross' devoid of
Editor's key points
It is unknown how sevoflurane affects the sensitivity of lung or renal carcinoma metastases to cisplatin. Sevoflurane promoted the metastatic potential and chemoresistance of renal cell carcinoma, but not of lung carcinoma. The distinct effect of sevoflurane on both cell lines was related to differential effects on TGF-b and osteopontin signaling.
adherent cells. Gap closure or healing was measured from images taken by a phase-contrast microscope and digital camera (Olympus CK30, Tokyo, Japan). The same four scratch areas from each well were analysed before and 24 h after treatment using ImageJ 1.35 (NIH, Bethesda, MD, USA) software. Wound healing was quantified as the mean percentage of the remaining gap area compared with the area of the initial gaps at t ¼ 0. 13 For siRNAmediated TGF-b1 and OPN knockdown, A549 and RCC4 cells at 70-80% confluence were transfected with 20 mM human-specific TGF-b1 siRNA: sense strand 5'-AGGUUAUU UCCGUGGGAUATT-3', antisense strand 5'-UAUCCCACGGAAAU AACCUAG-3'; or OPN siRNA: sense strand 5'-GGUUGUCCAGC AAUUAAUATT-3', antisense strand 5'-UAUUAAUUGCUGGA CAACCGT-3' (FlexiTube siRNA, Qiagen, Sussex, UK). A scrambled non-sense siRNA without specific gene-silencing activity was used as a negative control (Qiagen, Sussex, UK). Transfection was achieved using 20nM lipofectamine RNAi MAX (Invitrogen, Paisley, UK). Cells were then incubated for 24h at 37 C and 5% CO 2 , after which cells were washed with PBS (Sigma-Aldrich, Gillingham, UK) and RPMI medium was replaced before gas exposure.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde then rinsed with PBS (Sigma-Aldrich). Permeabilisation and blocking was achieved with 0.1% Triton X-100 in PBS (PBST) containing 10% normal donkey serum (Millipore) for one h. Cells were incubated in the dark overnight at 4 C in PBST with one of the following antibodies: rabbit anti-TGF-b (Abcam, Cambridge, UK), rabbit antiOsteopontin, (Abcam), rabbit anti-Smad3 (Abcam), or mouse anti-TGF-bRII (Abcam). Cells were then washed and incubated for one h in PBST with one of the following secondary antibodies: Rhodamine-conjugated donkey anti-rabbit IgG (Millipore, Oxford, UK), Fluorescein isothiocyanate (FITC)-conjugated donkey anti-rabbit IgG (Millipore) or FITCconjugated donkey antimouse IgG (Millipore), followed by washing and sealing with 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories). Images of 10 high-power fields at x20 magnification were generated from each cover slip using an AxioCam digital camera (Zeiss, Welwyn Garden City, UK) mounted on an Olympus BX60 microscope (Olympus, Middlesex, UK) with Zeiss KS-300 software (Zeiss). Images for each marker were obtained using identical exposure times and fluorescent intensity measured from five random cells and five background areas using ImageJ 1.35 software. Net mean intensity was calculated as mean cell minus background intensity for each of the 10 images obtained from the coverslip.
Statistical analysis
Data was expressed as mean (SEM). One-way ANOVA was performed with Tukey's post hoc multiple comparisons test using GraphPad Prism (GraphPad Software, La Jolla, CA, USA), except for immunocytochemistry data which was assessed nonparametrically using Kruskal-Wallis with Dunn's post hoc test. A P-value of < 0.05 was considered to be statistically significant. Power analysis revealed a group size of n¼6 to detect a difference in means of 0.5 to achieve a power of 0.8 (1-b) and a¼ 0.05.
Results
Sevoflurane inhibited cell viability but not migration of A549 cells
Sevoflurane exposed A549 cells had reduced cell viability compared with control at 24 h post gas exposure (0.394 vs 0.459) (P<0.01) and in the presence of DDP (0.490 vs 0.544) (P<0.001) (Fig. 1A) . Inhibition of TGF-bRI/II signalling with LY2109761 did not reverse the inhibitory effect of sevoflurane on A549 cell survival (P¼0.2028) (Fig. 1B) . Wound healing/migration was not inhibited by sevoflurane at 24 h [-1.6 (4.8%) vs 9(2.2%)] (P¼0.0506) (Fig. 1C and D) . Treatment of control cells with DDP inhibited cell migration and subsequent gap closure (P¼0.0001). To investigate possible additive inhibitory effects, gap expansion of DDP-treated cells with sevoflurane co-treatment was measured but this did not achieve statistical significance [-39 (22.6%) vs -9.3 (4.9%)], (P¼0.21) (Fig. 1C and D Sevoflurane upregulated expression of nuclear Smad3 in DDP-treated A549 cells TGF-b1 expression was unchanged in cells exposed to sevoflurane at 24 h (Fig. 2) . Nuclear Smad3 expression was elevated (Fig. 3 ). (Fig. 4B) . 
Sevoflurane enhanced cell viability of RCC4 cells
Sevoflurane enhanced migration of RCC4 cells
Migration was markedly enhanced in sevoflurane-treated cells compared with control at 24h after exposure (74.9% vs 52.1%) (P¼0.03) (Fig. 4C and D) . DDP-treated cells did not demonstrate a difference in migration, but cell confluence appears more preserved in cultures exposed to sevoflurane at 24 h posttreatment (Fig. 4C) .
OPN is involved in sevoflurane-mediated effects on migration of RCC4 cells OPN knockdown significantly reversed the positive effect of sevoflurane on migration in RCC4 at 24 h post gas exposure (42% vs 72.9%) (P¼0.017). Knockdown of TGF-b1 also appeared to reverse sevoflurane-mediated effects on RCC4 migration, although this did not achieve significance (P>0.05) (Fig. 4E) . Knockdown of both TGF-b1 and OPN had no effect on the migration of control cells (Fig. 4E) .
Sevoflurane upregulated expression of TGF-b1, TGFbRII and OPN but reduces nuclear Smad3 in DDPtreated RCC4 cells TGF-b1 expression was enhanced by sevoflurane exposure [22.4 (1.5) vs 11.7 (0.6)] (P<0.001) (Fig. 5A) . Levels of OPN were also markedly raised at 24 h post sevoflurane exposure [18.1 (1.4) vs 9.1 (0.5)] (P<0.001) (Fig. 5B) . Correspondingly, TGF-bRII was elevated in DDP-treated cells after exposure to sevoflurane [13.1 (0.5) vs 4.7 (0.4)] (P<0.001) (Fig. 6A) . Nuclear Smad3 expression was reduced in sevoflurane-treated cells [12.4 (0.99) vs 22.3 (1.4)] (P<0.001) (Fig. 6B) . 
Discussion
Our study provides evidence that sevoflurane promotes the metastatic potential of RCC cells, with associated upregulation of TGF-b and OPN signaling. Sevoflurane conferred cytoprotection to RCC cells in the presence of DDP at 24h and cellular confluence was more preserved at 48 h. This demonstrates an "antagonistic" action of sevoflurane on DDP cytotoxicity with enhanced chemoresistance, in keeping with findings by Brozovic and colleagues 14 Inhibition of TGF-b RI/II mitigated the promoting effects of sevoflurane, supporting the role of TGF-b in sevoflurane-mediated metastatic potentiation. TGF-b1 has been recognized to promote chemoresistance to DDP.
11
This study found a positive effect of sevoflurane on migration of RCC cells at 24 h, which agrees with effects found in breast cancer. 5 From a clinical perspective, this could indicate that induced phenotypic changes persist in residual cancer cells into the postoperative period per se. Sevoflurane treatment resulted in increased TGF-b1 and TGF-bRII and reduced nuclear Smad3 expression. This could illustrate a direct or indirect pro-tumorigenic and chemoresistance action of sevoflurane on RCC cells, involving uncoupling of the TGF-b1/Smad pathway, resulting in autoinduction of TGF-b1, 7 thus promoting tumour cell 'aggressiveness'. Knockdown of TGF-b1 may mitigate the promigratory effects of sevoflurane on RCC, supporting this as a mechanism. This effect concurs with our previous study on cell growth and migration of RCC4 cells after exposure to isoflurane, 15 and taken together, implies a class-effect of volatile agents on RCC. It has been reported that increased TGF-b1 and TGF-bRI/II expression and reduced Smad2/3 are possible biomarkers of tumorigenesis in RCC, 16 and studies have shown negative correlation of Smad3 to tumour grade and patient survival, 17 and negative association of Smad expression with migration. 18 Our findings suggest that this malignant phenotype is exaggerated by sevoflurane exposure. In contrast, renal ischaemiareperfusion injury studies show that sevoflurane is cytoprotective to renal proximal tubule epithelium via phosphorylation of cytoprotective kinases ERK and Akt, and that this is mediated via upstream TGF-b signalling, 19 specifically the TGF-b1/Smad3 pathway. Our data do not support the hypothesis that this could also be a mechanism of protumorigenesis, and instead find the opposite effect, of reduced TGF-b1/Smad3 activation. An explanation for this is that the differential response to TGF-b1 of normal and malignant cells could confer different pathways of cytoprotection from sevoflurane in normal renal epithelium and in RCC. This warrants further study. OPN is a metastasis-associated-protein and is implicated in chemoresistance in RCC. 10 RCC OPN expression was elevated with sevoflurane exposure consistent with findings in previous studies of normal renal epithelium. 20 Knockdown reversed the pro-migration effect of sevoflurane, suggesting OPN has a major role in the action of sevoflurane in RCC. In contrast, sevoflurane caused minor inhibition of cell viability of ADC, with enhanced chemosensitivity, but no significant change to cell migration. This inhibition was evident at 24 h but can persist to 48 h, as demonstrated by Liang and colleagues, 3 21 which is likely because of its induction of apoptosis. 3 22 Our data is the first to demonstrate upregulation of Smad3 signalling in ADC by a volatile agent. Unchanged levels of TGFb1 could indicate normal homeostatic regulation, with this pattern suggesting a possible functional 'sensitisation' of cells to TGF-b1. Sevoflurane could be changing the balance of signal transduction to favour the Smad pathway. This is supported by a recent studies showing inhibition of the non-Smad pathway components p38 MAPK, 21 Akt, 23 and ERK 24 by sevoflurane in lung. Gordian and colleagues 25 found exogenous TGF-b1 enhances the chemosensitivity of A549. However other studies have found that TGF-b/Smad promotes cell invasion and epithelial-mesenchymal transition in NSCLC, 26 and Smad activation correlates with poor prognosis in ADC. 27 An explanation for these contradictory findings may be that the inhibitory effects of sevoflurane on ADC are downstream to Smad3 activation, or potentiated by an alternative pathway, which should be investigated further. It is possible that the differences in behaviour to sevoflurane exposure of A549 and RCC4 originate from differences in the stage of carcinogenesis, which is related to TGF-b signalling alterations as a result of mutations in TGF-bRI/II and Smad proteins, and the presence of other transcription factors causing cross-talk differences. This is an assumption and warrants further study.
In summary, our data indicate a potential role of TGF-b and OPN signalling in sevoflurane-mediated metastatic potentiation of RCC, suggesting a possible increased risk of postoperative recurrence after sevoflurane anaesthesia, and conversely, minor inhibitory effects of sevoflurane on ADC.
Our findings indicate that sevoflurane may have different effects on different tumour types. In vivo studies that model the tumour microenvironment and clinical trials are urgently needed to evaluate this further.
